Related Experiment Video

Updated: Aug 7, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

1.9K

The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma

Maxime Borgeaud1, Floryane Kim1, Alex Friedlaender1,2

  • 1Oncology Department, University Hospital Geneva (HUG), 1205 Geneva, Switzerland.

Journal of Clinical Medicine
|March 11, 2023
PubMed

Insights

Immune checkpoint inhibitors (ICIs) improve survival for malignant pleural mesothelioma (MPM) patients. New strategies, including combination therapies and novel immunotherapies, are under investigation to enhance treatment efficacy for this rare cancer.

Area of Science:

  • Oncology
  • Immunotherapy
  • Thoracic Cancers

Background:

  • Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer often linked to asbestos exposure.
  • Prognosis for MPM is historically poor, with limited therapeutic advancements for over a decade.
  • Immune checkpoint inhibitors (ICIs) have emerged as a superior treatment option compared to chemotherapy, improving overall survival.

Purpose of the Study:

  • To review the current role of immunotherapy in managing malignant pleural mesothelioma.
  • To discuss emerging and future therapeutic strategies for MPM.
  • To highlight the need for predictive biomarkers for ICI response.

Main Methods:

  • Review of current clinical trial data and literature on immunotherapy for MPM.
  • Analysis of established and investigational immunotherapeutic approaches.
  • Evaluation of combination therapies and peri-operative immunotherapy.

Main Results:

  • ICIs have demonstrated improved survival outcomes in first- and later-line settings for MPM.
  • A substantial patient subset does not respond to ICIs, necessitating further research.
  • Clinical trials are exploring chemo-immunotherapy, ICI-anti-VEGF combinations, CAR-T cells, and dendritic cell vaccines.

Conclusions:

  • Immunotherapy, particularly ICIs, has significantly impacted MPM management.
  • Future directions include combination therapies, novel immunotherapeutic agents, and peri-operative immunotherapy.
  • Identifying biomarkers for ICI response remains crucial for optimizing patient selection and treatment outcomes.
Keywords:
biomarker mesotheliomaimmune checkpoint inhibitorsimmunotherapymalignant pleural mesothelioma

More Related Videos

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model09:31

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

9.3K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
606
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Pleural Disorders: Types and Brief Description01:30

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:
264
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.9K